Ustekinumab

Nature Reviews Drug Discovery

Volumn 8, Issue 5, 2009, Pages 355-356

  Reich, Kristian ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a DERMATOLOGIKUM HAMBURG   (Germany)

^b IQVIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; PLACEBO; STELARA; UNCLASSIFIED DRUG; USTEKINUMAB;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANTIBODIES, MONOCLONAL; HUMANS; PROTEIN BINDING; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 65449156130     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2878     Document Type: Article

References (22)

1. Schon, M. P. & Boehncke, W. H. Psoriasis. N. Engl. J. Med. 352 1899-1912 (2005).
2. Gottlieb, A. B. Psoriasis: Emerging therapeutic strategies. Nature Rev. Drug Discov. 4, 19-34 (2005).
3. Torti, D. C. & Feldman, S. R. Interleukin-12, interleukin-23, and psoriasis: Current prospects. J. Am. Acad. Dermatol. 57, 1059-1068 (2007).
4. Yawalkar, N. et al. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol. 111, 1053-1057 (1998).
5. Lee, E. et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125-130 (2004).
6. Hong, K. et al. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 162, 7480-7491 (1999).
7. European Medicines Agency (EMEA). European Public Assessment Report - Stelara. EMEA website [online], http://www.emea.europa.eu/ humandocs/PDFs/EPAR/stelara/H-958-PI-en.pdf (2008).
8. Kauffman, C. L. et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest. Dermatol. 123, 1037-1044 (2004).
9. Toichi, E. et al. An anti-IL-12p40 antibody downregulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177, 4917-4926 (2006).
10. Krueger, G. G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356 580-592 (2007).
11. Leonardi, C. L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665-1674 (2008).
12. Papp, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675-1684 (2008).
13. Dubertret, L. et al. European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. Br. J. Dermatol. 155, 729-736 (2006).
14. Rapp, S. R. et al. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 41, 401-407 (1999).
15. Reich, K. et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: A prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br. J. Dermatol. 28 Jan 2009 (epub ahead of print).
16. Augustin, M. et al. Disease severity, quality of life and health care in plaque-type psoriasis: A multicenter cross-sectional study in Germany. Dermatology 216, 366-372 (2008).
17. Reich, K. et al. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: A meta-analysis. Curr. Med. Res. Opin. 24, 1237-1254 (2008).
18. Schmitt J. et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br. J. Dermatol. 159, 513-526 (2008).
19. Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633-640 (2009).
20. IMS MIDAS (2008).
21. IMS PADDS (2008).
22. Novarro, G. RBC Capital Markets Equity Research Report (RBC CM Research Publishing, Toronto, 2008).